Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-15
2005-03-15
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
06867177
ABSTRACT:
The present invention provides a method of treating or preventing thrombotic or ischemic disorders in a subject which comprises administering an agent to the subject, wherein the agent inhibits ADP-mediated platelet aggregation by increasing ADP catabolism, and a method for determining whether a compound inhibits platelet aggregation by increasing ADP catabolism so as to treat or prevent thrombotic or ischemic disorders in a subject, comprising: (a) inducing thrombotic or ischemic disorders in an animal, which animal is an animal model for thrombotic or ischemic disorders; (b) measuring the stroke outcome in the animal, (c) measuring platelet deposition and/or fibrin deposition in ischemic tissue, and (d) comparing the stroke outcome in step (b) and the platelet deposition and/or fibrin deposition with that of the animal model in the absence of the compound so as to identify a compound capable of treating or preventing thrombotic or ischemic disorders in a subject.
REFERENCES:
patent: 5798241 (1998-08-01), Beaudoin et al.
Gura, T., 1997, Science, vol. 278, p. 1041-1042.*
Skolnick et al., 2999, TIBTECH, vol. 18, p. 34-39.*
Rudinger; Characteristics of the amino acids as components of a peptide hormone sequence, 1976, PEPTIDE HORMONES:1-7.*
Kaye et.al.; A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, 1990, Proc. Natl. Acad. Sci., vol. 87: 6922-6926.*
Fay et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 16(10): 1277-1284, Oct. 1996.*
Gayle et al. Journal of Clinical Investigation. 101(9): 1851-1859, May 1998.*
Guth et al. Journal of Cardiovascualr Pharmacology. 30(2): 261-272, 1997.*
Kaczmarek et al. Journal of Biological Chemistry. 271(51): 33116-33122, Oct. 1996.*
Abstract of McTaggart, et al. (Nov. 2, 1999) Cerebroprotective Role Of CD39 (Endothelial EctoADPase) in Murine Strain, SupplementCircualtion, 100(18):Page I-328, 1720 (Exhibit A).
International Search Report for International Application No. PCT/US00/22060, Nov. 14, 2000 (Exhibit C).
GenCore Accession No. WO4334,29 Dec. 1996, Beaudoin et al., WO 96/32471 A2 (UNIV. SHERBROOKE) Oct. 17, 1996 (Exhibit D).
Marcus, et al. (Mar. 1997) The Endothelial Cell Ecto-ADPase Responsible For Inhibition of Platelet Function Is CD39,The Journal of Clinical Investigation, 99(6): 1351-1360; (Exhibit E).
Kaczmarek, et al. (Dec. 1996) Identification and Characterization of CD39/Vascular ATP Diphosphohydorlase,The Journal of Biological Chemistry. 271(51):33116-33122 (Exhibit F).
Gayle, et al. (May 1998) Inhibition of Platelet Function by Recombinant Soluble Ecto-ADPase/CD39,The Journal of Clinical Investigation101(9): 1851-1859 (Exhibit G); and.
Guth, et al. (1997) Antagonism Of The GPIIb/IIa Receptor With The Nonpeptidic Molecule BIBU52: Inhibition Of Platelet Aggression In Vitro And Antithrombotic Efficacy In Vivo,Journal of Cardiovascular Pharmacology30(2):261-272 (Exhibit H).
Bowie E. J. W., et al., (1974)“The Bleeding Time” Progress in & Hemostasis and Thrombosis, Spaet TH (ed) 2d Ed, New York, Grune Statton, pp. 249-271 (Exhibit 1).
Broekmann, M. J., et al., (1991)“Inhibition of human Platelet Reactivity by Endothelium-Derived Relaxing Factor From Human Umbilical Vein Endothelial Cells in Suspension: Blockade of Aggregation and Secretion by an Aspirin-Insensitive Mechanism”, Blood, 78: 1033-1040 (Exhibit 2).
Bronner, L. L., et al., (1995) “Primary prevention of stroke”, N. Engl. J. Med. 333(21): 1392-1400 (Exhibit 3).
Buchanan M. R., et al., (1995) “Individual variation in the ASA effects of ASA on platelet function: Implication for the use of clinically”, Cardiovasc. Medicine, 11(3):221-227 (Exhibit 4).
Chiu, D., et al.,(1998) “Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice”, Stroke, 29: 18-22 (Exhibit 6).
Choudhri, T. F., et al.,(1997) “Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice”, Stroke, 28: 2296-2302 (Exhibit 7).
Choudhri, T. F., et al.,(1998) “Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation”,J. Clin. Invest., 102: 1301-1310 (Exhibit 8).
Connolly, E. S. Jr., et al., (1996) “Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke”, J. Clin. Invest., 97: 209-216 (Exhibit 9).
Connolly, E. S. Jr., et al.,(1997) “Exacerbation of cerebral injury in mice which express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke”,Circ. Res., 81: 304-310 (Exhibit 10).
Connolly, E. S. Jr., et al., (1996) “Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia”, Neurosurg., 38(3): 523-532 (Exhibit 11).
Eippel, D., (1998) “The results of CAPRIE, IST, and CAST”, Thrombosis Res., 92: S13-S16 (Exhibit 12).
Eitzman D. T., (1996) “Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-I gene”, J. Clin. Invest., 97:232-237 (Exhibit 13).
Erickson, L. A., et al., (1990)“ Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-I gene”, Nature, 346: 74-76 (Exhibit 14).
Gayle, R. B., et al., (1998) “Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39”,J. Clin. Invest, 101: 1851-1859 (Exhibit 15).
Grotenmeyer, K. H., (1991)“Effects of acetylsalicylic acid in stoke patients; evidence of nonresponders in a subpopulation of treated patients”, Thrombosis Res., 63: 587-593 (Exhibit 16).
Handa, M., & Guidotti, G., (1996)“Purification and Cloning of a Soluble ATP-Diphosphohydrolase (Apyrase) from Potato Tubers (Solanum tubersum)”, Biochem. Biophys. Res. Commun., 218, 916-923 (Exhibit 17).
Harbison, J. W., (1998)“ Clinical considerations in selecting Pharm antiplatelet therapy in cerebrovascular disease”, Am. J. Health Syst. 55, S17-S20 (Exhibit 18).
Hechler, B., et al., (1998) “The P2Y1receptor, necessary but not the sufficient to support full ADP-induced platelet aggregation, is not target of the drug clopidogrel”, Br. J. Haematol., 103: 858-866 (Exhibit 19).
Huang, Z., et al., (1994)“Effects of Cerebral Ischemia in Mice Deficient Neuronal Nitric Oxide Synthase”, Science, 265:1883-1885 (Exhibit 20).
Koch, R., Verhandlungen des X. Internationalem Medizinischen Congresses Berlin 1: 35-47 (1891).(Abstract) (Exhibit 21).
Lawson C. A., et al.,(1997) “Monocytes and tissue factor promote 99: thrombosis in a murine model of oxygen deprivation”, J. Clin. Invest., 1729-1738 (Exhibit 22).
Maeda K, et al.,(1998) “Differences in the cerebrovascular anatomy of C57black/6 and SV129 mice”, Neuroreport, 9(7):1317-1319 (Exhibit 23).
Majid A., et al., (1999) “Intrinsic, hemodynamic-independent differences in vulnerability to permanent focal cerebral ischemia in common mutant mouse strains”, 24th American Heart Association International Conference on Stoke and Cerebral CXJO-XXPY (Exhibit 24).
Maliszewski, C. R., et al., (1994)“The CD39 lymphoid cell activation antigen: Molecular cloning and structural characterization”, J. Immunol., 153: 3574-3583 (Exhibit 25).
Marcus, A. J.,& Safeir, L. B.,(1993) “Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis”, FASEB J., 7: 516-522 (Exhibit 26).
Marcus, A. J., (1999)“Platelets: Their role in hemostasis, thrombosis, and inflammation”, In Inflammation: Basic Principles and Clinical Correlates (EDS Gallin, J.I. & Snyderman, R.: 77-95 (Lippincott, Williams & Wilkins, Philadelphia (Exhi
Chen Shin-Lin
Cooper & Dunham LLP
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
CD39/ECTO-adpase as a treatment for thrombotic and ischemic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD39/ECTO-adpase as a treatment for thrombotic and ischemic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD39/ECTO-adpase as a treatment for thrombotic and ischemic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409978